Kensey Nash Exits Embolic Protection To Focus R&D Cash On Biomaterials
This article was originally published in The Gray Sheet
Kensey Nash's discontinuation of its embolic protection device business will free-up R&D resources for its biomaterials division, the firm says
You may also be interested in...
CMS has reversed its earlier proposal to significantly expand coverage of carotid stenting, dampening industry's hopes for a more open U.S. carotid stent market in the near term
Kensey Nash initiates pivotal trial enrollment for the ProGuard update to its TriActive embolic protection system in carotid stenting procedures. The Exton, Pa. firm hopes to complete the 300- to 400-patient multicenter trial to support a 510(k) submission by early 2008. The device is designed to reduce incidence of embolic stroke during carotid artery angioplasty using a balloon protection guidewire, flush catheter and an automated extraction system to remove debris. Kensey Nash says the ProGuard can be used in combination with any currently marketed carotid stent. A pilot trial, completed earlier this year, found no incidence of major stroke or death in 50 patients...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.